Understanding endocrine resistance: The critical need for sequential samples from clinical breast cancer and novel in vitro models

Breast Cancer Research

Volumn 7, Issue 5, 2005, Pages 187-189

  Gee, Julia M W ^a   Hutcheson, Iain R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CLINICAL TRIAL; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; HORMONE RESISTANCE; HUMAN; IN VITRO STUDY; PREDICTION; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 25844477516     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr1289     Document Type: Article

References (12)

1. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346S-354S.
2. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
3. Johnston SR: Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005, 15:889s-899s.
4. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999, 5:251-256.
5. Lonn U, Lonn S, Ingelman-Sundberg H, Nilsson B, Stenkvist B: c-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. Int J Cancer 1996, 69:273-277.
6. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005, 23:2469-2476.
7. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, et al.: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101:9393-9398.
8. Sabnis GJ, Jelovac D, Long B, Brodie A: The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005, 65:3903-3910.
9. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278:30458-30468.
10. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM: Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer 2004, 11:623-641.
11. Santen RJ, Song RX, Zhang Z, Yue W, Kumar R: Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 10: 337S-345S.
12. Hiscox S, Morgan L, Barrow D, Dutkowski C, Wakeling A, Nicholson RI: Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 2004, 21:201-212.